About Michael Bell

This author has not yet filled in any details.
So far Michael Bell has created 15 blog entries.
19 Jun, 2018

CIRCULOGENE’s Molecular Testing Can Potentially Improve Management of Advanced Ovarian Cancer Patients

CIRCULOGENE’s Molecular Testing Can Potentially Improve Management of Advanced Ovarian Cancer Patients Independent UAB study demonstrates potential value of company’s molecular testing in noninvasive, serial tracking of genomic changes in treatment-resistant ovarian cancer BIRMINGHAM, Ala.– [...]

29 May, 2018

REQUEST FOR APPLICATIONS CIRCULOGENE – RESEARCH SAMPLE PROFILING PILOT AWARD PROGRAM

REQUEST FOR APPLICATIONS CIRCULOGENE – RESEARCH SAMPLE PROFILING PILOT AWARD PROGRAM Applications due: 5pm EST on August 1, 2018 Award announcements: anticipated by September 15, 2018 Pilot Award Details: Made possible by Circulogene, this pilot [...]

23 May, 2018

CLINICAL SUCCESS STORY No. 4285

Advanced molecular genetics testing delivers lung cancer treatment decision with 5-day international turnaround. An Israeli oncologist referred his 63-year-old female lung #cancer patient to the #personalized cancer testing expertise of @CIRCULOGENE looking for a faster treatment [...]

23 May, 2018

CLINICAL SUCCESS STORY No. 4518

Single-tube liquid biopsy overcomes tissue biopsy failure to give oncologist personalized treatment decision guidance in matter of days. A southeastern oncologist treating a 66-year-old male with lung cancer was unable to obtain testing results due [...]

23 May, 2018

CLINICAL SUCCESS STORY No. 4521

Circulogene testing rapidly matches young patient with targeted therapy for rare non-small-cell lung cancer genetic variation. An oncologist referred a blood sample on his 44-year-old female non-small cell lung cancer (NSCLC) patient to @CIRCULOGENE for [...]

12 Jan, 2018

Pre-Analytical Assessment of Circulating Cell-Free DNA Prepared by An Isolation-Free Enrichment Technology

Publication: ACTA Scientific Cancer Biology Volume 2 Issue 1 January 2018 Abstract Quantity and quality of circulating cell-free DNA (cfDNA) from plasma is highly variable, with frequent contamination of larger, genomic DNA as a consequence [...]

3 Jan, 2018

CIRCULOGENE Announces International Licensing of Proprietary Molecular Diagnostics Testing Technology to Turkey-Based Laboratory

CIRCULOGENE Announces International Licensing of Proprietary Molecular Diagnostics Testing Technology to Turkey-Based Laboratory Company expands single-blood-tube, cancer-targeted therapy and immunotherapy testing to parts of Europe, Africa, the Middle East and Commonwealth of Independent States (CIS) [...]

29 Nov, 2017

CIRCULOGENE Appoints Dr. Glen J. Weiss as Chief Medical Officer

BIRMINGHAM, Ala. ­­­– CIRCULOGENE, advancing precision medicine through personalized molecular genetics testing, has named medical oncologist and cancer researcher Glen J. Weiss, M.D., MBA, as Chief Medical Officer. Dr. Weiss will oversee and advance the [...]

17 Nov, 2017

Circulogene Featured in Genetic Engineering & Biotechnology News

November 15, 2017 Circulogene's Chen-Hsiung Yeh, Ph.D., CSO, was recently featured in a new article titled, Cell-Free DNA Drives Liquid Biopsy Testing published by Genetic Engineering & Biotechnology News. "Chen-Hsiung Yeh, Ph.D., CSO, Circulogene Theranostics, believes that what makes [...]

15 Nov, 2017

CIRCULOGENE Introduces Single-Tube, Blood-Based Microsatellite Instability (MSI) Biomarker Testing for Multiple Cancers

MSI Diagnostic Testing Available for Precision Cancer Immunotherapy BIRMINGHAM, Ala.--(BUSINESS WIRE)-- CIRCULOGENE, a leading liquid biopsy company advancing precision medicine through personalized molecular genetics testing, has announced the availability of microsatellite instability (MSI) biomarker testing for [...]